NCT07046221View on ClinicalTrials.gov

Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

August 1, 2027

Study Completion Date

August 1, 2030

Conditions
Esophagus Cancer
Interventions
DRUG

Tislelizumab

200mg，d1，q3w，1years

DRUG

Albumin-Bound Paclitaxel

125mg/m2，d1，d8，q3w，2cycles

DRUG

cis-platinum

75mg/m2，d1，q3w，2cycles

PROCEDURE

Surgery

Radical resection of esophageal cancer

RADIATION

Radiation

50.5Gy/28f

DRUG

Nedaplatin

80-100mg/m2，d1，q3w，2cycles

DRUG

Carboplatin

AUC=5，d1，q3w，2cycles

All Listed Sponsors
lead

Fujian Cancer Hospital

OTHER_GOV